DTIL
NASDAQPrecision BioSciences Inc.
Website
News25/Ratings5
News · 26 weeks48-70%
2025-10-262026-04-19
Mix2190d
- Other9(43%)
- SEC Filings7(33%)
- Insider4(19%)
- Earnings1(5%)
Latest news
25 items- SECSEC Form DEFA14A filed by Precision BioSciences Inc.DEFA14A - PRECISION BIOSCIENCES INC (0001357874) (Filer)
- SECSEC Form DEF 14A filed by Precision BioSciences Inc.DEF 14A - PRECISION BIOSCIENCES INC (0001357874) (Filer)
- PRPrecision BioSciences to Participate in the 25th Annual Needham Virtual Healthcare ConferencePrecision BioSciences, Inc. (NASDAQ:DTIL), a clinical stage gene editing company utilizing its novel proprietary ARCUS® platform to develop in vivo gene editing therapies for high unmet need diseases, today announced the Company will participate in the 25th Annual Needham Virtual Healthcare Conference being held April 13-16, 2026. 25th Annual Needham Virtual Healthcare Conference Format: Virtual Corporate presentation Date/Time: Tuesday, April 14, 2026 at 9:30am ET Webcast Link: Precision BioSciences Virtual Presentation Link If you are interested in meeting with the Precision team during the conference, please reach out to your Needham representative. A replay of the presentation wil
- SECSEC Form PRE 14A filed by Precision BioSciences Inc.PRE 14A - PRECISION BIOSCIENCES INC (0001357874) (Filer)
- PRiECURE Selected for U.S. FDA Chemistry, Manufacturing, and Controls Development and Readiness Pilot Program to Support Manufacturing Readiness of ECUR-506 Ahead of Planned BLA SubmissionFDA Chemistry, Manufacturing, and Controls (CMC) Development and Readiness Pilot (CDRP) program supports manufacturing readiness for therapies with expedited clinical development timelines ECUR-506 selected as one of up to nine programs annually Participation enables additional FDA engagement on CMC strategy ahead of a potential BLA submission iECURE, Inc., a clinical-stage genome editing company developing variant-agnostic in vivo targeted gene insertion therapies for the treatment of severe, inherited, neurometabolic disorders, today announced that the U.S. Food and Drug Administration (FDA) has selected ECUR-506, the company's investigational in vivo targeted gene insertion therapy
- SECPrecision BioSciences Inc. filed SEC Form 8-K: Regulation FD Disclosure, Financial Statements and Exhibits8-K - PRECISION BIOSCIENCES INC (0001357874) (Filer)
- SECSEC Form 10-K filed by Precision BioSciences Inc.10-K - PRECISION BIOSCIENCES INC (0001357874) (Filer)
- SECPrecision BioSciences Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits8-K - PRECISION BIOSCIENCES INC (0001357874) (Filer)
- PRPrecision BioSciences Receives U.S. Patent Allowances Covering the PBGENE-HBV ProgramPrecision BioSciences, Inc. (NASDAQ:DTIL), a clinical stage gene editing company utilizing its novel proprietary ARCUS® platform to develop in vivo gene editing therapies for high unmet need diseases, today announced that it has received two Notices of Allowance from the U.S. Patent and Trademark Office (USPTO) for patent applications relating to the Company's PBGENE-HBV program. The first Notice of Allowance relates to U.S. Patent Application No. 19/347,136, titled "Engineered meganucleases having specificity for a recognition sequence in the Hepatitis B virus genome." The '136 application includes composition of matter claims that, when granted, will encompass the ARCUS nuclease utilize
- PRPrecision BioSciences Presents Preclinical PBGENE-DMD Data Highlighting Durable Dystrophin Expression and Functional Benefit at the Muscular Dystrophy Association Clinical & Scientific Conference 2026– Findings reinforce differentiated in vivo gene editing approach designed for durable functional muscle improvement through satellite cell editing – – PBGENE-DMD treatment in a humanized DMD mouse model demonstrates improvements in muscle pathology and biomarkers of muscle damage – – PBGENE-DMD shows durable dystrophin protein restoration in humanized DMD mice across key muscle groups, including cardiac, diaphragm, and skeletal muscles – Precision BioSciences, Inc. (NASDAQ:DTIL), a clinical stage gene editing company utilizing its novel proprietary ARCUS® platform to develop in vivo gene editing therapies for high unmet need diseases, today announced presentation of new preclinical s
- PRPrecision BioSciences to Report Fourth Quarter and Fiscal Year 2025 Results on March 12, 2026Precision BioSciences, Inc. (NASDAQ:DTIL), a clinical stage gene editing company utilizing its novel proprietary ARCUS® platform to develop in vivo gene editing therapies for high unmet need diseases, today announced that it will publish financial results for the fourth quarter 2025 and provide a business update on March 12, 2026. About Precision BioSciences, Inc. Precision BioSciences, Inc. is a clinical stage gene editing company dedicated to improving life (DTIL) with its novel and proprietary ARCUS® genome editing platform that differs from other gene editing technologies in the way it cuts, its smaller size, and its simpler structure. These features are intended for ARCUS nucleases
- PRPrecision BioSciences Receives FDA Fast Track Designation for PBGENE-DMD and Announces Duchenne Muscular Dystrophy Investor Event– Fast Track designation aims to facilitate development and expedite review of drugs, such as PBGENE-DMD to treat serious conditions like Duchenne muscular dystrophy – – March 17, 2026 virtual webinar to feature expert insights on potential clinical utility of PBGENE-DMD for patients with Duchenne muscular dystrophy and the planned Phase 1/2 FUNCTION-DMD clinical study – Precision BioSciences, Inc. (NASDAQ:DTIL), a clinical stage gene editing company utilizing its novel proprietary ARCUS® platform to develop in vivo gene editing therapies for high unmet need diseases, today announced that the U.S. Food and Drug Administration (FDA) has granted Fast Track designation to PBGENE-DMD for th
- PRPrecision BioSciences Receives $7.5M in Proceeds from TG Therapeutics for Azer-cel Clinical Milestone in Multiple Sclerosis– Milestone payments include $5.25 million cash and $2.25 million purchase of Precision stock– – Cash received supports Precision's expected cash runway through 2028 and strategic focus on in vivo gene editing pipeline – Precision BioSciences, Inc. (NASDAQ:DTIL), a clinical stage gene editing company utilizing its novel proprietary ARCUS® platform to develop in vivo gene editing therapies for high unmet need diseases, today announced the achievement of a clinical milestone under its license agreement with TG Therapeutics, Inc. (NASDAQ:TGTX). The milestone payment for azercabtagene zapreleucel (azer-cel) was triggered by progress of a Phase 1 clinical trial of azer-cel in progressive for
- INSIDERPresident and CEO Amoroso Michael converted options into 67,797 shares and sold $78,947 worth of shares (20,559 units at $3.84), increasing direct ownership by 24% to 243,392 units (SEC Form 4)4 - PRECISION BIOSCIENCES INC (0001357874) (Issuer)
- INSIDERChief Financial Officer Kelly John Alexander converted options into 27,584 shares and sold $31,292 worth of shares (8,149 units at $3.84), increasing direct ownership by 18% to 125,883 units (SEC Form 4)4 - PRECISION BIOSCIENCES INC (0001357874) (Issuer)
- INSIDERGeneral Counsel and Secretary Scimeca Dario converted options into 16,667 shares and sold $18,912 worth of shares (4,925 units at $3.84), increasing direct ownership by 26% to 56,457 units (SEC Form 4)4 - PRECISION BIOSCIENCES INC (0001357874) (Issuer)
- INSIDERChief Research Officer Smith J. Jefferson converted options into 16,667 shares and sold $18,912 worth of shares (4,925 units at $3.84), increasing direct ownership by 11% to 121,926 units (SEC Form 4)4 - PRECISION BIOSCIENCES INC (0001357874) (Issuer)
- PRPrecision BioSciences Announces Presentation at the 2026 Muscular Dystrophy Association Clinical & Scientific ConferencePrecision BioSciences, Inc. (NASDAQ:DTIL), a clinical stage gene editing company utilizing its novel proprietary ARCUS® platform to develop in vivo gene editing therapies for high unmet need diseases, today announced that new preclinical study data supporting the potential safety and long-term efficacy of PBGENE-DMD has been selected as a poster presentation at the upcoming 2026 Muscular Dystrophy Association (MDA) Clinical & Scientific Conference taking place March 8-11 in Orlando, Florida. Details of the presentation: Abstract title: PBGENE-DMD gene editing treatment leads to safe and long-term functional improvement in humanized DMD-disease mouse model Publication number: 142M Type o
- SECAmendment: SEC Form SCHEDULE 13G/A filed by Precision BioSciences Inc.SCHEDULE 13G/A - PRECISION BIOSCIENCES INC (0001357874) (Subject)
- SECPrecision BioSciences Inc. filed SEC Form 8-K: Regulation FD Disclosure, Results of Operations and Financial Condition, Other Events, Financial Statements and Exhibits8-K - PRECISION BIOSCIENCES INC (0001357874) (Filer)
- PRPrecision BioSciences Receives U.S. FDA Clearance of Investigational New Drug Application for First-in-Class PBGENE-DMD for Treatment of Duchenne Muscular Dystrophy– U.S. FDA Study May Proceed notification enables initiation of clinical trial site activation for the FUNCTION-DMD Phase 1/2 clinical study in patients with Duchenne muscular dystrophy (DMD) – – Institutional Review Board (IRB) process is underway at multiple world-class DMD clinical trial sites – – PBGENE-DMD is an in vivo gene editing investigational product designed to correct the underlying genetic cause of DMD through a novel one-time gene editing therapy – – Company plans to host a virtual event in March after the Muscular Dystrophy Association conference to discuss PBGENE-DMD and the FUNCTION-DMD clinical study with participation from key opinion leaders including patient advo
- INSIDERPresident and CEO Amoroso Michael converted options into 115,378 shares and sold $145,112 worth of shares (34,799 units at $4.17), increasing direct ownership by 70% to 196,154 units (SEC Form 4)4 - PRECISION BIOSCIENCES INC (0001357874) (Issuer)
- INSIDERGeneral Counsel and Secretary Scimeca Dario converted options into 25,311 shares and sold $35,682 worth of shares (8,854 units at $4.03), increasing direct ownership by 58% to 44,715 units (SEC Form 4)4 - PRECISION BIOSCIENCES INC (0001357874) (Issuer)
- INSIDERChief Financial Officer Kelly John Alexander converted options into 44,363 shares and sold $61,308 worth of shares (15,213 units at $4.03), increasing direct ownership by 38% to 106,448 units (SEC Form 4)4 - PRECISION BIOSCIENCES INC (0001357874) (Issuer)
- INSIDERChief Research Officer Smith J. Jefferson converted options into 29,166 shares and sold $41,106 worth of shares (10,200 units at $4.03), increasing direct ownership by 21% to 110,184 units (SEC Form 4)4 - PRECISION BIOSCIENCES INC (0001357874) (Issuer)